Metsera
About Metsera
Metsera is a clinical-stage biotechnology company focused on engineering and developing NuSH (nutrient-stimulated hormone) therapies for obesity and related diseases. The company pursues injectable and oral, ultra-long-acting therapies designed to be scalable and tolerable, with a strong emphasis on peptide engineering, translational science, and large-scale manufacturing. Metsera aims to deliver convenient and affordable obesity treatments and is operating within the biotech and pharmaceutical landscape; the site notes that Metsera was acquired by Pfizer, positioning the venture within Pfizer's portfolio. The content centers on obesity therapeutics and metabolic health, with global implications for weight management and related conditions.
Recent News
Biotech in 2025: A Retrospective
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Pfizer Shares Edge Higher on Strong Oncology Data Amid Flat 2026 Revenue Guidance
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
The Top 10 PharmTech Videos of 2025
Pfizer’s Metsera-Originated Monthly GLP-1 Cuts Weight by 10.5% at Six Months
Amneal Sets $3.1B 2026 Revenue Target, Leverages GLP‑1 Manufacturing Partnership
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
Amneal Projects $3.1B 2026 Revenue, Leverages Pfizer GLP‑1 Manufacturing Deal
Obesity Biotech Verdiva Plans Big Year of Data, Explores Deals
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Recent Deals
No recent deals for this company.
